CapLaw-2025-09

  • BioVersys AG conducts IPO on SIX Swiss Exchange

    On 29 January 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, opened the 2025 Initial Public Offering (IPO) season and announced the launch of its IPO on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process….

    By

    CapLaw

    Reference:
    Read more: BioVersys AG conducts IPO on SIX Swiss Exchange